Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00032045
Phase
PHASE2
Status
Completed

Conditions

  • Intraocular Melanoma
  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • gp100 antigen — BIOLOGICAL
  • incomplete Freund's adjuvant — BIOLOGICAL
  • ipilimumab — BIOLOGICAL

Study Details

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with monoclonal antibody therapy in treating patients who have stage IV melanoma.

Key Dates

Start date
Jan 31, 2002
Status verified
Mar 2003
Completion
Aug 31, 2006

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MD

Related Studies